Research groups All groups >>

Lines of research

• Cardiac pharmacology. Electrophysiological mechanisms involved in cardiac arrhythmias. Endogenous and pharmacological regulation of cardiac ion channels.
• Genetic basis of arrhythmias and of drug-induced arrhythmias.
• Vascular pharmacology. Signalling pathways involved in the origin of and target organ damage produced by pulmonary and systemic hypertension. Endogenous and pharmacological regulation of ion channels in vascular smooth muscle cells.
• Preclinical assessment of new cardiovascular drugs.
• Nutrients with a pharmacological impact and potential health benefits

A variety of approaches are used in developing these research lines, including the recording of action potentials (glass microelectrodes), ion currents (patch-clamp), contractile activity, and changes in intracellular calcium concentration, and techniques from cell biology (western blot), immunohistochemistry, immunocytochemistry, and ion channel modelling.

Current projects financed by public institutions:

1. NO modulation of cardiac K channels that participate in human atrial repolarization
2. PKCz interaction with p62 and Kv channels in pulmonary vasoconstriction induced by thromboxane A2
3. Pulmonary vasoconstriction induced by hypoxy and vasoactive factors: role of Kv and PKCz
4. Role of statins in controlling K currents that determine atrial repolarization

Latest publications

• Tamargo J, Le Heuzey JY, Mabo P Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur. J. Clin. Pharmacol. 2015; 71: 549-67

  View abstract

• Tamargo J, Caballero R, Delpón E Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 129-52

  View abstract

• Tamargo J, Duarte J, Ruilope LM New antihypertensive drugs under development. Curr. Med. Chem. 2015; 22: 305-42

  View abstract

• Daimi H, Lozano-Velasco E, Haj Khelil A, Chibani JB, Barana A, Amorós I, González de la Fuente M, Caballero R, Aranega A, Franco D Regulation of SCN5A by microRNAs: miR-219 modulates SCN5A transcript expression and the effects of flecainide intoxication in mice. Heart Rhythm 2015; 12: 1333-42

  View abstract

• Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur. Heart J. 2015; 36: 2677-80

  View abstract

• Toral M, Gómez-Guzmán M, Jimenez R, Romero M, Zarzuelo MJ, Utrilla MP, Hermenegildo C, Cogolludo A, Perez-Vizcaino F, Gálvez J, Duarte J Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J. Hypertens. 2015; 33: 1831-44

  View abstract

• López-Farré AJ, Rodríguez-Sierra P, Modrego J, Segura A, Martín-Palacios N, Saiz AM, Zamorano-León JJ, Duarte J, Serrano J, Moñux G Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients. Br J Clin Pharmacol 2014; 78: 1366-77

  View abstract

• Tamargo J, Caballero R, Delpón E New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope? Discov Med 2014; 18: 249-54

  View abstract

• Tamargo J, Segura J, Ruilope LM Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 2014; 15: 527-47

  View abstract

• Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Tamargo J 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J. 2014; 35: 3033-69, 3069a-3069k

  View abstract

All publications